US 11,718,667 B2
Optimized antibody variable regions
Gregory Moore, Arcadia, CA (US); Matthew Bernett, Monrovia, CA (US); Rumana Rashid, Arcadia, CA (US); and John Desjarlais, Pasadena, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Monrovia, CA (US)
Filed on Jun. 4, 2021, as Appl. No. 17/339,774.
Application 17/339,774 is a continuation of application No. 16/162,172, filed on Oct. 16, 2018, granted, now 11,053,316.
Application 16/162,172 is a continuation of application No. 14/207,489, filed on Mar. 12, 2014, granted, now 10,131,710, issued on Nov. 20, 2018.
Application 14/207,489 is a continuation in part of application No. 14/205,248, filed on Mar. 11, 2014, granted, now 9,650,446, issued on May 16, 2017.
Application 14/205,248 is a continuation in part of application No. 14/205,227, filed on Mar. 11, 2014, abandoned.
Application 14/205,227 is a continuation in part of application No. 14/200,652, filed on Mar. 7, 2014, granted, now 10,968,276, issued on Apr. 6, 2021.
Application 14/200,652 is a continuation in part of application No. 14/200,821, filed on Mar. 7, 2014, granted, now 9,605,084, issued on Mar. 28, 2017.
Application 14/200,821 is a continuation in part of application No. 14/155,344, filed on Jan. 14, 2014, granted, now 9,701,759, issued on Nov. 26, 2019.
Application 14/155,344 is a continuation in part of application No. 14/155,334, filed on Jan. 14, 2014, granted, now 10,738,132, issued on Aug. 11, 2020.
Application 14/155,334 is a continuation in part of application No. 14/155,248, filed on Jan. 14, 2014, granted, now 10,487,155, issued on Jul. 11, 2017.
Claims priority of provisional application 61/938,095, filed on Feb. 10, 2014.
Claims priority of provisional application 61/913,832, filed on Dec. 9, 2013.
Claims priority of provisional application 61/913,870, filed on Dec. 9, 2013.
Claims priority of provisional application 61/913,879, filed on Dec. 9, 2013.
Claims priority of provisional application 61/818,410, filed on May 1, 2013.
Claims priority of provisional application 61/818,344, filed on May 1, 2013.
Claims priority of provisional application 61/818,153, filed on May 1, 2013.
Claims priority of provisional application 61/818,401, filed on May 1, 2013.
Claims priority of provisional application 61/794,695, filed on Mar. 15, 2013.
Claims priority of provisional application 61/794,896, filed on Mar. 15, 2013.
Claims priority of provisional application 61/780,334, filed on Mar. 13, 2013.
Claims priority of provisional application 61/780,310, filed on Mar. 13, 2013.
Claims priority of provisional application 61/778,157, filed on Mar. 12, 2013.
Claims priority of provisional application 61/778,148, filed on Mar. 12, 2013.
Claims priority of provisional application 61/764,954, filed on Feb. 14, 2013.
Claims priority of provisional application 61/752,348, filed on Jan. 14, 2013.
Prior Publication US 2022/0380462 A1, Dec. 1, 2022
Int. Cl. C07K 1/18 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C07K 16/00 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 1/18 (2013.01); C07K 16/00 (2013.01); C07K 16/2809 (2013.01); C07K 16/468 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/62 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/94 (2013.01)] 1 Claim
 
1. A composition comprising an anti-CD3 variable region having a sequence comprising a vhCDR1 having the sequence T-Y-A-M-Xaa1, wherein Xaa1 is N, S or H (SEQ ID NO:435), a vhCDR2 having the sequence R-I-R-S-K-Xaa1-N-Xaa2-Y-A-T-Xaa3-Y-Y-A-Xaa4-S-V-K-G, wherein Xaa1 is Y or A, Xaa2 is N or S, Xaa3 is Y or A and Xaa4 is D or A (SEQ ID NO:436), a vhCDR3 having the sequence H-G-N-F-G-Xaa1-S-Y-V-S-W-F-Xaa2-Y, wherein Xaa1 is N, D or Q and Xaa2 is A or D (SEQ ID NO:437), a vlCDR1 having the sequence Xaa1-S-S-T-G-A-V-T-Xaa2-Xaa3-Xaa4-Y-A-N, wherein Xaa1 is G, R or K, Xaa2 is T or S, Xaa3 is S or G and Xaa4 is N or H, (SEQ ID NO:438), a vlCDR2 having the sequence Xaa1-T-N-Xaa2-R-A-Xaa3, wherein Xaa1 is G or D, Xaa2 is K or N, and Xaa3 is P or S (SEQ ID NO:439) and a vlCDR3 having the sequence Xaa1-L-W-Y-S-N-Xaa2-W-V, wherein Xaa1 is A or L and Xaa2 is L or H (SEQ ID NO:440).